All News
Filter News
Found 386 articles
-
Kamada Ltd. Announces Study In Support Of Alpha-1 Antitrypsin For The Treatment Of Type-1 Diabetes Published In The Journal Of Diabetes Science And Technology
10/21/2014
-
Kamada Ltd. Extends Glassia Agreement With Baxter International, Inc.
9/29/2014
-
Kamada Ltd. Reports Final Results From Phase 2/3 Clinical Trial Of Inhaled Alpha-1 Antitrypsin To Treat Alpha-1 Antitrypsin Deficiency
9/4/2014
-
Kamada Ltd. Reports Second Quarter Financial Results
8/14/2014
-
Kamada Ltd. To Host Second Quarter Financial Results Conference Call On Thursday, August 14, 2014
8/6/2014
-
Kamada Ltd. Crashes After Key Trial Failure
5/19/2014
-
Kamada Ltd. To Announce Results From Phase 2/3 Clinical Trial Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency On May 16
5/15/2014
-
Kamada Ltd. Reports First Quarter Financial Results
5/8/2014
-
Kamada Ltd. Announces Significantly Improved Infusion Rate For Glassia®
4/24/2014
-
Kamada Ltd. Announces U.S. Proof-Of-Concept Study With Glassia® For Graft-Versus-Host Disease
4/3/2014
-
Kamada Ltd. Announces Initiation Of A Phase 2 U.S. Clinical Trial Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency
3/24/2014
-
Kamada Ltd. To Report Top-Line Data From Phase 2/3 Clinical Trial Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency By Late April Or Early May
3/21/2014
-
Kamada Ltd. Initiates Phase 2/3 Clinical Trial Of Glassia To Treat Newly Diagnosed Pediatric Patients With Type 1 Diabetes
3/5/2014
-
Kamada Ltd. Completes Enrollment In U.S. Pivotal Clinical Trial With Kamrab As A Post-Exposure Treatment For Rabies
3/4/2014
-
Kamada Ltd. To Ring The NASDAQ Stock Market Opening Bell On February 25, 2014
2/24/2014
-
Kamada Ltd. Reports 2013 Fourth Quarter And Full Year Financial Results
2/5/2014
-
Kamada Ltd. To Host Fourth Quarter And Full Year 2013 Financial Results Conference Call On Wednesday, February 5, 2014
1/31/2014
-
Kamada Ltd. Announces Completion Of Pivotal Phase 2/3 Clinical Trial In Europe And Canada Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency
12/11/2013
-
Kamada Ltd. Announces Appointment Of Amir London As Senior Vice President, Business Development
12/9/2013
-
Kamada Ltd. Reports New Data From an Extension Study of Its Phase I/II Trial With Glassia in Pediatric Patients With Type 1 Diabetes
10/31/2013